Clinical Trial Update: Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial of ONTAK (denileukin diftitox) in cutaneous T-cell lymphoma patients (including mycosis fungoides and Sézary syndrome) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sézary Syndrome

Drugs mentioned

• ONTAK (denileukin diftitox)

Snippet

Sponsor: Eisai Inc. | Conditions: Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides | Phase 4 | Status: COMPLETED